Alkaline Phosphatase Purification Reducing Host Cell Proteins

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The development of a pharmaceutical composition of alkaline phosphatase for pharmaceutical use is hindered by high host cell protein (HCP) content and unwanted particle formation during stability testing, which is not adequately addressed by standard downstream processing (DSP) and formulation methods.

Innovation Solution

A method involving affinity purification using a specific ligand, optimized washing and elution buffers, and a mixed mode purification step to reduce HCP content and prevent particle formation, including the use of buffers with components like Arg, urea, ethylene glycol, and Mg/Zn ions to enhance the stability and purity of the alkaline phosphatase composition.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If standard downstream processing (DSP) methods are used, then the production process is simple and cost-effective, but the host cell protein (HCP) content remains high and particle formation occurs

Engineering Contradiction:
ImproveHCP content reductionVSAvoidpurification process complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The purification process is divided into distinct stages: initial affinity purification using a specific ligand, intermediate washing steps with optimized buffers, and final elution. This segmentation allows each step to target specific contaminants while preserving the alkaline phosphatase, achieving HCP reduction below 100 ppm through systematic separation rather than attempting single-step removal

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

Optimized washing buffers containing components like Arg, urea, ethylene glycol, and Mg/Zn ions serve as intermediaries between the bound alkaline phosphatase and the HCP contaminants. These buffer components selectively interact with HCP to facilitate their removal while maintaining the stability and binding of the target enzyme to the ligand

Inventive Principle:
Principle #24Intermediary (Mediator)

2Stability of the object's composition

If standard formulation methods are used, then the formulation process is straightforward, but visible particle formation occurs during stability testing

Engineering Contradiction:
Improvephysical stabilityVSAvoidformulation process simplicity
Core Design Contradiction:
Stability of the object's compositionVSEase of manufacture

Solution Approach 1:

The formulation employs specific parameter optimizations including pH adjustment to alkaline conditions, precise control of buffer component concentrations (Arg, urea, ethylene glycol, Mg/Zn ions), and controlled ionic strength. These parameter changes create a formulation environment that prevents particle formation during stability testing while maintaining enzyme activity and solubility

Inventive Principle:
Principle #35Parameter changes

3Manufacturing precision

If affinity purification with specific ligand is used, then HCP content is reduced effectively, but the purification process becomes more complex

Engineering Contradiction:
ImprovepurityVSAvoidpurification process complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The affinity purification system uses a specific ligand that selectively binds to alkaline phosphatase, extracting it from the complex mixture of host cell proteins. The optimized washing buffers then remove HCP that co-purified with the enzyme, achieving effective separation and purification through selective binding and differential washing

Inventive Principle:
Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method effectively reduces HCP content to below 100 ppm and prevents visible particle formation during stability testing, ensuring the physical stability and compliance of the alkaline phosphatase composition with regulatory norms.

Implementation Method 1

A method involving affinity purification using a specific ligand

Methodology Applied
Scientific EffectAffinity interaction: Adsorption

Implementation Method 2

buffers with components like Arg, urea, ethylene glycol, and Mg/Zn ions to enhance the stability and purity of the alkaline phosphatase composition

Methodology Applied
Scientific EffectMetal ion stabilization:

Data Source

PatentEP3461891B1Downstream processing of an alkaline phosphatase
Publication Date: 2020.07.01 AM PHARMA
  • EP3461891B1 patent drawingFigure 1
  • EP3461891B1 patent drawingFigure 2
  • EP3461891B1 patent drawingFigure 3

AI summary

The invention relates to the field of downstream processing (DSP) of an alkaline phosphatase (AP). More specifically, it relates to a method for reducing host cell protein content in a composition comprising AP. The invention further relates to a composition comprising an AP and a reduced content of a host cell protein.